STZ vs. CPRX
STZ (Constellation Brands, Inc.) and CPRX (Catalyst Pharmaceuticals, Inc.) are both stocks. STZ operates in Beverages - Wineries & Distilleries (Consumer Defensive), while CPRX operates in Biotechnology (Healthcare). Over the past 10 years, STZ returned 1.01%/yr vs 46.26%/yr for CPRX. At a 0.14 correlation, their price movements are largely independent.
Performance
STZ vs. CPRX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, STZ achieves a 9.07% return, which is significantly lower than CPRX's 34.36% return. Over the past 10 years, STZ has underperformed CPRX with an annualized return of 1.01%, while CPRX has yielded a comparatively higher 46.26% annualized return.
STZ
- 1D
- 3.77%
- 1M
- 4.33%
- YTD
- 9.07%
- 6M
- 2.07%
- 1Y
- -7.48%
- 3Y*
- -13.90%
- 5Y*
- -7.36%
- 10Y*
- 1.01%
CPRX
- 1D
- -0.03%
- 1M
- 0.58%
- YTD
- 34.36%
- 6M
- 32.77%
- 1Y
- 33.28%
- 3Y*
- 39.03%
- 5Y*
- 40.44%
- 10Y*
- 46.26%
STZ vs. CPRX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
STZ Constellation Brands, Inc. | 9.07% | -35.99% | -7.11% | 5.83% | -6.43% | 16.12% | 17.41% | 19.85% | -28.73% | 50.69% |
CPRX Catalyst Pharmaceuticals, Inc. | 34.36% | 11.84% | 24.15% | -9.62% | 174.74% | 102.69% | -10.93% | 95.31% | -50.90% | 272.38% |
Correlation
The correlation between STZ and CPRX is 0.12, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.12 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.12 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.19 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.20 |
Correlation (All Time) Calculated using the full available price history since Nov 8, 2006 | 0.14 |
Fundamentals
STZ:
$25.79B
CPRX:
$3.98B
STZ:
$11.23
CPRX:
$1.74
STZ:
13.22
CPRX:
18.02
STZ:
8.24
CPRX:
0.32
STZ:
2.84
CPRX:
6.68
STZ:
3.08
CPRX:
3.93
STZ:
$9.14B
CPRX:
$596.96M
STZ:
$4.71B
CPRX:
$378.23M
STZ:
$3.05B
CPRX:
$313.50M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
STZ vs. CPRX — Risk / Return Rank
STZ
CPRX
STZ vs. CPRX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Constellation Brands, Inc. (STZ) and Catalyst Pharmaceuticals, Inc. (CPRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| STZ | CPRX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.23 | ||
| Sortino ratioReturn per unit of downside risk | -1.71 | ||
| Omega ratioGain probability vs. loss probability | 0.97 | 1.18 | -0.22 |
| Calmar ratioReturn relative to maximum drawdown | -0.39 | 1.52 | -1.91 |
| Martin ratioReturn relative to average drawdown | -0.68 | 3.46 | -4.14 |
Loading charts...
Drawdowns
STZ vs. CPRX - Drawdown Comparison
The maximum STZ drawdown since its inception was -67.39%, smaller than the maximum CPRX drawdown of -94.25%. Use the drawdown chart below to compare losses from any high point for STZ and CPRX.
Loading charts...
Drawdown Indicators
| STZ | CPRX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -67.39% | -94.25% | +26.86% |
Max Drawdown (1Y)Largest decline over 1 year | -26.51% | -19.18% | -7.33% |
Max Drawdown (3Y)Largest decline over 3 years | -51.28% | -27.29% | -23.99% |
Max Drawdown (5Y)Largest decline over 5 years | -51.28% | -45.37% | -5.91% |
Max Drawdown (10Y)Largest decline over 10 years | -53.53% | -64.87% | +11.34% |
Current DrawdownCurrent decline from peak | -42.57% | -0.03% | -42.54% |
Average DrawdownAverage peak-to-trough decline | -16.60% | -51.96% | +35.36% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 15.01% | 9.84% | +5.17% |
Volatility
STZ vs. CPRX - Volatility Comparison
Constellation Brands, Inc. (STZ) has a higher volatility of 8.54% compared to Catalyst Pharmaceuticals, Inc. (CPRX) at 0.47%. This indicates that STZ's price experiences larger fluctuations and is considered to be riskier than CPRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| STZ | CPRX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 8.54% | 0.47% | +8.07% |
Volatility (6M)Calculated over the trailing 6-month period | 23.36% | 23.17% | +0.19% |
Volatility (1Y)Calculated over the trailing 1-year period | 30.17% | 33.28% | -3.11% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 24.56% | 47.77% | -23.21% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 26.96% | 60.39% | -33.43% |
Dividends
STZ vs. CPRX - Dividend Comparison
STZ's dividend yield for the trailing twelve months is around 2.75%, while CPRX has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CPRX Catalyst Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
STZ Constellation Brands, Inc. | 2.75% | 2.95% | 1.77% | 1.44% | 1.36% | 1.21% | 1.37% | 1.58% | 1.70% | 0.86% | 0.98% | 0.65% |
Financials
STZ vs. CPRX - Financials Comparison
This section allows you to compare key financial metrics between Constellation Brands, Inc. and Catalyst Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
STZ vs. CPRX - Profitability Comparison
STZ - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Constellation Brands, Inc. reported a gross profit of 941.60M and revenue of 1.92B. Therefore, the gross margin over that period was 49.0%.
CPRX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported a gross profit of 0.00 and revenue of 149.39M. Therefore, the gross margin over that period was 0.0%.
STZ - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Constellation Brands, Inc. reported an operating income of 357.10M and revenue of 1.92B, resulting in an operating margin of 18.6%.
CPRX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported an operating income of 73.23M and revenue of 149.39M, resulting in an operating margin of 49.0%.
STZ - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Constellation Brands, Inc. reported a net income of 477.70M and revenue of 1.92B, resulting in a net margin of 24.9%.
CPRX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported a net income of 63.73M and revenue of 149.39M, resulting in a net margin of 42.7%.
Frequently Asked Questions
STZ and CPRX have a correlation of 0.12, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
STZ has higher volatility (8.54%) compared to CPRX (0.47%). In terms of maximum drawdown, STZ dropped -67.39% vs CPRX's -94.25%.
CPRX currently has the higher Sharpe Ratio (0.89 vs -0.34), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for STZ and CPRX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer